Table 1.
Preoperative findings and demographic data.
| Variables | Number of Cases (%) |
|---|---|
| Sex | |
| male | 12 (92.3) |
| female | 1 (7.7) |
| ASA * | |
| I | 1 (7.7) |
| II | 7 (53.8) |
| III | 4 (30.8) |
| IV | 1 (7.7) |
| Neoadjuvant therapy | |
| none | 1 (7.7) |
| chemotherapy (FLOT) | 7 (53.8) |
| radiochemotherapy (CROSS) ** | 5 (38.5) |
| Histopathologic entity | |
| squamous cell carcinoma | 3 (23.0) |
| adenocarcinoma | 8 (61.5) |
| MANEC, adenosquamous | 2 (15.4) |
| Risk factors | |
| smoking | 8 (61.5) |
| COPD *** Gold II | 6 (46.2) |
| diabetes mellitus type II | 1 (7.7) |
| arterial hypertension | 5 (38.5) |
| pulmonary embolism | 1 (7.7) |
| renal insufficiency | 1 (7.7) |
* ASA: American Society of Anesthesiologists-classification; ** ChemoRadiotherapy for esophageal cancer followed by Surgery Study)/perioperative chemotherapy with FLOT (fluorouracil–leucovorin–oxaliplatin–docetaxel; *** COPD: Chronic Obstructive Pulmonary Disease.